[CAS NO. 426-13-1] Fluorometholone
PRODUCTS SPECIFICATIONS [426-13-1]
DESCRIPTION [426-13-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 376.46 |
| Molecular Formula | C22H29FO4 |
| SMILES | CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])C[C@H](C)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)=O)=O |
1 Publications Citing Use of MCE
Summary
Fluorometholone, a synthetic glucocorticoid, is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic properties. Fluorometholone can be used for the research of dry eye [1] .
IC50 & Target
glucocorticoid receptor [1]
In Vitro
Fluorometholone (25-100 nM; 12 hours, 24 hours) increases the gene expression of MUC1, MUC4, MUC16 and MUC19 in the conjunctival and corneal epithelial cells through activation of glucocorticoid receptors
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01288404 | Ramathibodi Hospital |
Pterygium of the Conjunctiva and Cornea
|
January 2008 | Not Applicable |
| NCT03747614 | Zhongshan Ophthalmic Center, Sun Yat-sen University |
Dry Eye Syndromes|Inflammation|Microvessels
|
June 30, 2017 | Phase 4 |
| NCT04149210 | Massachusetts Eye and Ear Infirmary|University of Pennsylvania|London School of Hygiene and Tropical Medicine|Berhan Public Health and Eye Care Consultancy PLC|The Fred Hollows Foundation, Ethiopia|The Fred Hollows Foundation, Australia |
Trachomatous Trichiasis (TT)|Eye Diseases|Eyelid Diseases|Trachomatous|Trichiasis
|
June 14, 2021 | Phase 3 |
| NCT01448213 | Price Vision Group |
Fuchs´ Dystrophy|Bullous Keratopathy
|
October 2011 | Phase 2 |
| NCT00824811 | M.D. Anderson Cancer Center|Allergan |
Epiphora
|
June 2009 | Phase 2 |
| NCT00707421 | Universitaire Ziekenhuizen KU Leuven|Funding for Research in Ophthalmology (FRO) |
Glaucoma|Trabeculectomy|Fibrosis|Intraocular Pressure
|
July 2005 | Phase 3 |
| NCT02974387 | Dr Salouti Eye Research Center|Shiraz University of Medical Sciences |
Must be PRK Candidate
|
April 2017 | Phase 4 |
| NCT02030990 | United States Naval Medical Center, San Diego |
Corneal Opacity
|
August 2014 | Phase 2|Phase 3 |
| NCT05313828 | Sohag University |
Corneal Ulcer
|
March 18, 2022 | |
| NCT02816905 | Cairo University |
Intraocular Pressure
|
October 2015 | Phase 4 |
| NCT01949454 | University of Pennsylvania|Lions Club International Foundation|Berhan Public Health and Eye Care Consultancy PLC|Grarbet Tehadiso Mahber |
Trichiasis|Trachoma|Bilamellar Tarsal Rotation
|
November 2013 | Not Applicable |
| NCT05587231 | Navy Medical Center San Diego |
Steroid Ophthalmic Insert
|
October 2022 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 50 mg/mL ( 132.82 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6563 mL | 13.2816 mL | 26.5632 mL |
| 5 mM | 0.5313 mL | 2.6563 mL | 5.3126 mL |
| 10 mM | 0.2656 mL | 1.3282 mL | 2.6563 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
Synonyms